4-(4-Ethyl-phenyl)-1,2,3,6-tetrahydro-pyridin | 92039-53-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(4-Ethyl-phenyl)-1,2,3,6-tetrahydro-pyridin
• 英文别名: 4-(4-Ethylphenyl)-1,2,3,6-tetrahydropyridine
• CAS: 92039-53-7
• 化学式: C₁₃H₁₇N
• mdl: MFCD08689310
• 分子量: 187.285
• InChiKey: ZQNRDVQYZGESMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(4-Ethyl-phenyl)-1,2,3,6-tetrahydro-pyridin 、 Ethyl 2-ethoxy-3-[4-(2-methylsulfonyloxyethoxy)phenyl]propanoate 在 potassium carbonate 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl 2-ethoxy-3-[4-[2-[4-(4-ethylphenyl)-3,6-dihydro-2H-pyridin-1-yl]ethoxy]phenyl]propanoate
  参考文献：
  名称：

  Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists

  摘要：

  Aryl-tetrahydropyridine derivatives were prepared and their PPAR alpha/gamma dual agonistic activities were evaluated. Among them, compound (S)-5b was identified as a potent PPAR alpha/gamma dual agonist with an EC50 of 1.73 and 0.64 mu M in hPPAR alpha and gamma, respectively. In diabetic (db/db) mice, compound (S)-5b showed good glucose lowering efficacy and favorable pharmacokinetic properties. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.020
• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 4-(4-Ethyl-phenyl)-1,2,3,6-tetrahydro-pyridin
  参考文献：
  名称：

  Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists

  摘要：

  Aryl-tetrahydropyridine derivatives were prepared and their PPAR alpha/gamma dual agonistic activities were evaluated. Among them, compound (S)-5b was identified as a potent PPAR alpha/gamma dual agonist with an EC50 of 1.73 and 0.64 mu M in hPPAR alpha and gamma, respectively. In diabetic (db/db) mice, compound (S)-5b showed good glucose lowering efficacy and favorable pharmacokinetic properties. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.020

文献信息

• COMPOUNDS AND THEIR USES 707
  申请人：Hallam Matthew

  公开号：US20090023746A1

  公开（公告）日：2009-01-22

  The present invention relates to isoquinolinone derivatives of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明涉及公式（I）的异喹啉酮衍生物：其中R1，R2，R3，R4，R5，R6和R7如本文所定义；它们的制备方法，含有它们的制药组合物以及它们在治疗中的用途。
• ISOQUINOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ( COPD ) AND ASTHMA
  申请人：AstraZeneca AB

  公开号：EP2144881B1

  公开（公告）日：2012-06-20
• US8012979B2
  申请人：——

  公开号：US8012979B2

  公开（公告）日：2011-09-06
• [EN] NEW COMPOUNDS AND THEIR USES 707<br/>[FR] NOUVEAUX COMPOSES ET LEURS UTILISATIONS
  申请人：ASTRAZENECA AB

  公开号：WO2008122765A1

  公开（公告）日：2008-10-16

  [EN] The present invention relates to isoquinolinone derivatives of formula (I): should be wherein R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
  [FR] L'invention concerne des dérivés d'isoquinolinone de formule (I), dans laquelle R¹, R², R³, R⁴, R⁵, R⁶ et R⁷ sont tels que définis dans la description. L'invention concerne également des procédés de préparation associés, des compositions pharmaceutiques contenant ces dérivés ainsi que leur utilisation thérapeutique.
• Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists
  作者：Eunkyung Kim、Chan Sun Park、Taedong Han、Myung-Ho Bae、Wonee Chong、Choong Hyun Lee、Young Ah Shin、Byung-Nak Ahn、Mi Kyung Kim、Chang Yell Shin、Moon Ho Son、Jin Kwan Kim、Ho Sang Moon、Hyun Joo Shim、Eun Jung Kim、Soon Hoe Kim、Joong In Lim、Chun Ho Lee

  DOI：10.1016/j.bmcl.2008.08.020

  日期：2008.9

  Aryl-tetrahydropyridine derivatives were prepared and their PPAR alpha/gamma dual agonistic activities were evaluated. Among them, compound (S)-5b was identified as a potent PPAR alpha/gamma dual agonist with an EC50 of 1.73 and 0.64 mu M in hPPAR alpha and gamma, respectively. In diabetic (db/db) mice, compound (S)-5b showed good glucose lowering efficacy and favorable pharmacokinetic properties. (C) 2008 Elsevier Ltd. All rights reserved.